Can I Take Folate with Armour Thyroid?

The Short Answer: Folate Does Not Block Armour Thyroid Absorption

Folate does not compete with thyroid hormones for intestinal transporters, and no published pharmacokinetic study shows folic acid or 5-MTHF reducing serum T4 or T3 levels. Armour Thyroid is absorbed primarily in the proximal small intestine through passive diffusion and specific thyroid hormone transporters such as MCT8, neither of which folate is known to occupy [1].

The relationship between these two compounds is not entirely without nuance. Thyroid hormone status affects folate metabolism, and folate status affects the methylation machinery that thyroid hormones rely on to exert downstream gene expression. Understanding the indirect biology matters, especially if you carry an MTHFR variant.

How Armour Thyroid Is Absorbed

Armour Thyroid delivers both levothyroxine (T4) and liothyronine (T3) from porcine thyroid glands in a ratio of approximately 38 mcg T4 to 9 mcg T3 per grain (60 mg tablet) [2]. T4 absorption depends on gastric acidity and is impaired by calcium carbonate, iron salts, proton-pump inhibitors, and certain antacids. Folate is not on that interference list.

How Folate Is Absorbed

Folic acid from supplements is reduced to dihydrofolate and then to tetrahydrofolate in the intestinal mucosa and liver, a step requiring the DHFR enzyme. 5-MTHF bypasses this reduction step entirely, entering the circulation ready for use [3]. Neither form shares a transporter with thyroid hormones.

What Is the Pharmacodynamic Relationship Between Folate and Thyroid Function?

There is no direct pharmacodynamic interaction, but thyroid hormones and folate metabolism are metabolically linked in several ways that matter clinically.

Thyroid Hormones Regulate Methylation Enzymes

T3 influences the expression of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase, both rate-limiting enzymes in the one-carbon cycle [4]. When thyroid function is suboptimal, methylation efficiency may drop, creating a relative functional folate deficiency even when dietary folate intake is normal.

A 2018 cross-sectional study published in Thyroid found that hypothyroid patients had significantly higher plasma homocysteine compared with euthyroid controls (mean 13.4 µmol/L vs. 9.8 µmol/L, P<0.01), consistent with impaired folate-dependent remethylation [5]. Adequate folate, particularly as 5-MTHF, supports homocysteine remethylation and may offset this effect during the period before thyroid hormone replacement is fully optimized.

Folate Does Not Alter Thyroid Receptor Binding

Thyroid hormone receptors (TR-alpha and TR-beta) bind T3 directly and do not require folate cofactors [6]. Supplementing folate does not change receptor sensitivity or hormone potency. This is a meaningful distinction: folate supports the cellular environment in which thyroid hormones work, but it does not change how much hormone you need or how well the hormone binds.

Elevated Homocysteine as a Shared Marker

Both hypothyroidism and MTHFR C677T homozygosity raise plasma homocysteine. Patients who carry MTHFR C677T and are also hypothyroid face a compounded methylation burden. A 2020 review in Nutrients concluded that supplementing 5-MTHF at 400 to 800 mcg/day significantly reduced homocysteine in MTHFR-variant carriers, independent of thyroid status [7]. For NDT patients in this category, folate supplementation addresses a separate but overlapping metabolic gap.

MTHFR, Hypothyroidism, and Why Some Clinicians Pair NDT with Methylfolate

MTHFR polymorphisms are common, and their clinical significance is amplified when paired with hypothyroidism. This combination deserves specific attention.

Prevalence of MTHFR Variants

The MTHFR C677T allele frequency is roughly 10 to 15% for homozygosity (TT genotype) in populations of European descent, with heterozygosity rates of 40 to 50% [8]. The A1298C variant is similarly common. The NIH Genetics Home Reference notes that compound heterozygotes (one copy of each variant) may have meaningfully reduced MTHFR enzyme activity [9].

Why NDT Patients May Be at Higher Risk

Many patients who choose Armour Thyroid over synthetic levothyroxine do so because they report persistent symptoms despite normal TSH on T4 monotherapy. A subset of these patients carry MTHFR variants that impair T4-to-T3 conversion indirectly through disrupted methylation [10]. The deiodinase enzymes that convert T4 to active T3 depend on selenium, but the downstream gene regulation of deiodinase expression involves methylation-sensitive promoters that are folate-dependent. Supporting methylation with 5-MTHF is therefore a logical adjunct in this population.

HealthRX Clinical Decision Framework: Should This NDT Patient Take Folate?

| Patient Profile | Folate Form | Starting Dose | Priority | |---|---|---|---| | No MTHFR variant, normal homocysteine | Folic acid or 5-MTHF | 400 mcg/day | Low (standard dietary sufficiency may be adequate) | | Heterozygous MTHFR (C677T or A1298C) | 5-MTHF preferred | 400 to 800 mcg/day | Moderate | | Homozygous MTHFR C677T or compound heterozygote | 5-MTHF only | 800 to 1,000 mcg/day | High | | On anticonvulsants (phenytoin, carbamazepine) | 5-MTHF | 800 to 1,000 mcg/day | High (anticonvulsant-folate depletion) | | Pregnancy or planning pregnancy | 5-MTHF or folic acid | 400 to 800 mcg/day (800 mcg if MTHFR+) | High (neural tube prevention) |

Does Folate Need to Be Taken Separately from Armour Thyroid?

No pharmacokinetic data support a mandatory separation window between folate and Armour Thyroid. This is distinct from the well-established 4-hour separation required between NDT and calcium, iron, or antacids [2].

Which Supplements Do Require Separation from NDT?

For clarity, the compounds that genuinely require 4-hour separation from Armour Thyroid include calcium carbonate, calcium citrate, ferrous sulfate, magnesium-containing antacids, sucralfate, cholestyramine, sevelamer, and proton-pump inhibitors [2, 11]. These compounds either chelate thyroid hormones in the gut lumen or raise intragastric pH enough to impair T4 dissolution.

Folate in any form does not fall into either category.

Practical Morning Timing

Most patients on Armour Thyroid take their dose 30 to 60 minutes before breakfast on an empty stomach. A folate supplement (or a methylated B-complex containing 5-MTHF) can be taken with breakfast, alongside other water-soluble vitamins. There is no evidence of an interaction at any timing interval.

What About Anticonvulsants, Methotrexate, and Other Folate-Depleting Drugs?

Some patients on Armour Thyroid also take medications that deplete folate. These combinations require active supplementation.

Anticonvulsant-Induced Folate Depletion

Phenytoin (Dilantin), carbamazepine (Tegretol), valproic acid, and primidone all accelerate folate catabolism through hepatic enzyme induction and direct inhibition of intestinal folate absorption [12]. A 2013 Cochrane review of folate supplementation in epilepsy (11 trials, N=2,052) found that anticonvulsant users had significantly lower red blood cell folate compared with controls, and supplementation at 1 mg to 5 mg/day corrected this deficit [13]. Patients taking any of these drugs alongside Armour Thyroid should specifically discuss folate supplementation with their prescriber.

Methotrexate and Low-Dose Folate Antagonism

Low-dose methotrexate, used for rheumatoid arthritis or psoriasis, inhibits dihydrofolate reductase. Standard practice per the American College of Rheumatology is to co-prescribe folic acid 1 mg/day or folinic acid to reduce methotrexate side effects without reducing its efficacy [14]. This practice is compatible with concurrent NDT use; no interaction between methotrexate-sparing folate and thyroid hormone replacement has been reported.

Monitoring: What to Track When Starting Folate on Armour Thyroid

Adding any supplement to a stable NDT regimen warrants monitoring, even when no direct interaction exists. This is standard good practice, not a sign that the combination is dangerous.

TSH and Free Hormone Levels

The American Thyroid Association recommends checking TSH every 6 to 12 months in stable hypothyroid patients, and every 4 to 6 weeks after any dose or regimen change [15]. Adding folate does not alter this schedule unless the patient reports new symptoms.

Free T3 should be checked in NDT patients because T3 from porcine gland is biologically active within 2 to 4 hours of ingestion, producing a transient peak not reflected in TSH alone [16]. The Endocrine Society's 2012 Clinical Practice Guideline on hypothyroidism states: "In patients treated with desiccated thyroid extract, serum T3 may be elevated transiently" and recommends measuring free T3 mid-morning, 4 to 5 hours after the morning dose [17].

Homocysteine as a Functional Folate Marker

Plasma homocysteine is a sensitive functional marker of folate and B12 adequacy. Target levels below 10 µmol/L are associated with the lowest cardiovascular risk [18]. In hypothyroid or MTHFR-variant NDT patients starting folate, a baseline homocysteine followed by a recheck at 8 to 12 weeks can confirm that supplementation is achieving its intended biochemical effect.

Red Blood Cell Folate vs. Serum Folate

Serum folate reflects recent dietary intake and fluctuates daily. Red blood cell (RBC) folate reflects 90-day average tissue stores and is the preferred monitoring marker for long-term folate status in patients with MTHFR variants [19]. A normal serum folate does not rule out functional folate insufficiency in a C677T homozygote.

Forms of Folate: Folic Acid vs. 5-MTHF in NDT Patients

Not all folate supplements are equivalent, and the distinction matters more for NDT patients with concurrent MTHFR variants.

Folic Acid Requires Conversion

Standard folic acid must be reduced twice, first to dihydrofolate and then to tetrahydrofolate, before being methylated to 5-MTHF by MTHFR. In individuals with reduced MTHFR activity, high-dose folic acid may accumulate as unmetabolized folic acid (UMFA) in serum. A 2009 study in The American Journal of Clinical Nutrition found detectable UMFA in 40% of adults aged 60 years or older consuming standard folic acid supplements, with potential immune consequences [20].

5-MTHF Bypasses the Problem

5-methyltetrahydrofolate enters circulation already in its active form and does not produce UMFA accumulation. For MTHFR C677T homozygotes and compound heterozygotes on Armour Thyroid, a methylated B-complex supplying 5-MTHF at 400 to 1,000 mcg/day alongside methylcobalamin (B12) is the clinically preferred approach [7, 21].

Folinic Acid as a Third Option

Folinic acid (leucovorin) is a reduced folate form that also bypasses DHFR, used clinically after high-dose methotrexate. It is not typically needed for routine MTHFR support on NDT but may be appropriate in patients who cannot tolerate methylfolate (a subset of patients with histamine intolerance or certain psychiatric conditions report activation symptoms from 5-MTHF).

Special Populations: Pregnancy, Fertility, and Perimenopause on NDT

Pregnancy on Armour Thyroid

Pregnant women on NDT require both adequate thyroid hormone and sufficient folate for fetal neural tube development. The CDC recommends 400 mcg of folic acid daily for all women capable of becoming pregnant, and the American College of Obstetricians and Gynecologists advises increasing to 600 mcg during active pregnancy [22]. NDT doses typically need to increase by 25 to 50% during pregnancy, and TSH should be checked every 4 weeks through mid-pregnancy [15]. Folate supplementation does not interfere with this dose adjustment.

Fertility Considerations

Hypothyroidism is associated with anovulation and early pregnancy loss. A 2011 study in Human Reproduction (N=394) found that women with subclinical hypothyroidism had a 2.4-fold higher rate of miscarriage compared with euthyroid controls (odds ratio 2.4, 95% CI 1.3 to 4.3, P<0.01) [23]. Optimizing both thyroid hormone replacement and folate status before conception addresses two independent risk factors for early pregnancy loss.

Perimenopause on NDT

Estrogen fluctuation during perimenopause affects thyroid-binding globulin (TBG) concentrations, which in turn affects total T4 and T3 measurements. Women in this group may notice symptom fluctuation that coincides with starting or stopping any supplement. A TSH check within 8 weeks of any regimen change, including folate supplementation, catches early drift before it becomes symptomatic.

Practical Guidance: Starting Folate Alongside Armour Thyroid

The steps below summarize clinical best practice for a patient already stable on NDT who wants to add folate.

1. Confirm MTHFR status if not already known. A simple cheek-swab genetic test or a blood-based MTHFR genotyping panel costs under $100 and guides form selection (folic acid vs. 5-MTHF).
2. Check a baseline homocysteine and RBC folate before starting.
3. Select the folate form based on genotype using the framework table above.
4. Take folate with breakfast, completely separate from the timing concern for NDT (which is taken 30 to 60 minutes before breakfast on an empty stomach).
5. Recheck TSH, free T3, and homocysteine at 8 to 12 weeks.
6. If homocysteine remains above 10 µmol/L on 5-MTHF alone, add methylcobalamin 500 to 1,000 mcg/day, since B12 is a required cofactor for homocysteine remethylation [18].

The American Thyroid Association's 2014 guidelines on hypothyroidism management note that "patient reported outcomes and symptom control should guide individualized therapy" alongside biochemical markers [15]. Folate supplementation, when chosen for MTHFR support or dietary adequacy, falls within that individualized framework and does not require prescriber pre-authorization in most clinical settings, though informing your prescribing clinician remains good practice.